Summary

The oral direct factor Xa inhibitor apixaban was superior to aspirin therapy for the reduction of stroke or systemic embolism risk in patients with atrial fibrillation who were unsuitable for vitamin K antagonist therapy according to the phase III Apixaban versus Acetylsalicylic Acid to Prevent Strokes [AVERROES; NCT00496769] trial.